enGene Therapeutics Inc
ENGN
NASDAQ
Biotechnology
$1.70
USD
+0.01 (+0.59%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $113.21M
Volume 918.7K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-126.85M
TTM
-58.8%
YoY
Operating Cash Flow
$-110.00M
TTM
-45.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 6.9 | 7.4 | 7.8 | 8.9 | 9.8 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 27.1 | 29.9 | 39.5 | 31.2 | 32.0 |
Operating Income | -27.1 | -29.9 | -39.5 | -31.2 | -32.0 |
EBITDA | -27.0 | -29.8 | -39.3 | -31.0 | -31.8 |
Other Income / Expense | -0.2 | -0.3 | -0.1 | -0.6 | -0.2 |
Total Other Income / Expense | 1.5 | 1.2 | 1.1 | 1.4 | 1.7 |
Income Before Income Taxes | -25.6 | -28.8 | -38.4 | -29.8 | -30.2 |
Income Taxes | 0.2 | 0.2 | -0.5 | 0.0 | 0.0 |
Net Income | -25.8 | -29.0 | -37.9 | -29.8 | -30.2 |
Consolidated Net Income / Loss | -25.8 | -29.0 | -37.9 | -29.8 | -30.2 |
Net Income Attributable to Common Shareholders | -25.8 | -29.0 | -37.9 | -29.8 | -30.2 |
Basic EPS | -$0.51 | -$0.57 | -$0.74 | -$0.44 | -$0.43 |
Diluted EPS | -$0.51 | -$0.57 | -$0.74 | -$0.44 | -$0.43 |
Basic Shares Outstanding | 51.0M | 51.1M | 51.4M | 67.3M | 69.7M |
Diluted Shares Outstanding | 51.0M | 51.1M | 51.4M | 67.3M | 69.7M |